Quantitative Assessment of Philadelphia Chromosome Using Interphase/Hypermetaphase FISH and Toxicity after STI571 Treatment in Chronic Myelogenous Leukemia.
- Author:
Kyung Eun LEE
1
;
Seock Ah IM
;
Eun Sun YOO
;
Ji Young AHN
;
Sun Mi LEE
;
Jung Won HUH
;
Soon Nam LEE
;
Wha Soon CHUNG
;
Chu Myung SEONG
Author Information
1. Section of Hematology and Oncology, Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
CML (Chronic myelogenous leukemia);
STI571 (GleevecTM);
FISH (Fluorescence in situ hybridization);
Philadelphia (Ph1) chromosome
- MeSH:
Adult;
Bone Marrow;
Chromosome Aberrations;
Cohort Studies;
Compassionate Use Trials;
Cytogenetics;
Fever;
Fluorescence;
Follow-Up Studies;
Fusion Proteins, bcr-abl;
Hemorrhage;
Humans;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*;
Molecular Biology;
Neutropenia;
Philadelphia Chromosome*;
Phosphotransferases;
Signal Transduction;
Thrombocytopenia;
Imatinib Mesylate
- From:Korean Journal of Hematology
2002;37(1):1-8
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Chronic Myelogenous Leukemia (CML) is the first proven disease in which gene abnormality, t(9;22)(q34;q11) can cause the disease to occur in humans. Recently, targeted therapy with STI571 (GleevecTM), signal transduction inhibitor for BCR-ABL kinase was developed and can induce cytogenetic remission in patients with CML. Hypermetaphase-FISH (HMF)/Interphase-FISH (I-FISH, Fluorescence in situ hybridization) aiming specific chromosomal abnormalities are unambiguous quantitative molecular genetic methods for individual Philadelphia (Ph1) chromosome positive cells. We evaluated the change of Ph1 chromosome in CML patients during STI571 therapy using HMF/I- FISH. METHODS: Twenty one patients with CML were treated with STI571 which was provided from Norvatis pharmaceutical company as Expanded Access Program for Compassionate Use from May 2001 at the doses of 200-600 mg/day orally. Median age of this cohort was 37 years old and median follow up duration was 113 days (48~165 days). HMF or I-FISH using bone marrow or peripheral blood were performed on the sample at baseline, day 14, day 28 and then monthly. RESULTS: Complete cytogenetic responses which were assessed by HMF/I-FISH counting several hundreds cells were found in 8 of 21 patients. Among them, 4 of 10 chronic phase, 2 of 2 accelerate phase and 2 of 8 blastic crisis patients achieved cytogenetic complete response. One patient with blastic crisis was relapsed after achieving cytogenetic complete response. Grade III-IV thrombocytopenia and neutropenia were noticed in 8 and in 7 patients respectively, but there were no major bleeding episodes nor neutropenic fever. CONCLUSION: BCR-ABL tyrosine kinase inhibitor, STI571 was tolerable for patients with CML. The majority of patients achieved hematologic remission and 8 out of 21 patients achieved complete cytogenetic response regardless of their disease stage. Cytogenetic response of Ph1 chromosome can be quantified accurately with HMF/I-FISH.
